Get the full picture
Sign in to uncover key details.
Vogenx
Business Services · North Carolina, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3920 S Alston Ave, Durham, North Carolin...Phone Number
(919) 659-5677Website
www.vogenx.comRevenue
-Industry
About Vogenx
Vogenx, Inc. is a clinical-stage life science and drug development company headquartered in Durham, North Carolina. The company focuses on developing novel therapeutics for diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, gastroparesis, and obesity. Its lead compound is a first-in-class, oral, small molecule drug candidate (mizagliflozin) designed to inhibit postprandial glucose absorption and reduce excessive insulin and gastric inhibitory peptide secretion. Vogenx is dedicated to improving outcomes for patients suffering from serious metabolic and gastrointestinal conditions through innovative, science-driven treatment approaches.Explore more
Vogenx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Vogenx
Compare insights from companies similar to Vogenx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Vogenx Tech Stack
A closer look at the technologies used by Vogenx
See more technologies
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vogenx
Sign Up For FreeTo access detailed company insights
Vogenx, Inc. is a clinical-stage life science and drug development company headquartered in Durham, North Carolina. The company focuses on developing novel therapeutics for diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, gastroparesis, and obesity. Its lead compound is a first-in-class, oral, small... Read More
